SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its recent earnings report, where the company exceeded revenue and EPS expectations, yet the stock experienced a notable after-hours decline. This unexpected dip, despite positive top and bottom-line results, has fueled community discussions ranging from claims of market manipulation to strong conviction among long-term investors buying the dip. Investors are actively debating the implications of the company's guidance, including its Q1 EPS forecast and projected doubling of ad revenue, alongside ongoing discussions about the strategic acquisition of Warner Bros. Discovery assets.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community discussion surges following CEO Ryan Cohen's significant additional share purchases, fueling speculation that the stock's bottom is in and a new 'meme season' could be on the horizon. Investors are actively debating a potential short squeeze and eagerly awaiting any communication from "Roaring Kitty," while noting the stock's notable resilience amidst broader market weakness.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending following compelling Phase 1 clinical trial data for its oral drug soquelitinib in atopic dermatitis, which demonstrated strong efficacy and a favorable safety profile, driving the stock to significant gains. Community discussion highlights both excitement for its potential as a best-in-class treatment for a large market and concerns surrounding a recently announced stock offering, with opinions split on whether it's a strategic funding move or a precursor to dilution. Investors are keenly watching the long-term implications of this early-stage therapeutic and its market validation.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention due to a highly positive FDA update for its ANKTIVA bladder cancer treatment, as the agency will not require new clinical trials for its resubmission, greatly de-risking the approval pathway. This development, combined with high short interest and massive trading volume, is driving strong community conviction around a potential short squeeze and the therapy's broader "cure for cancer" implications across multiple indications, even as the stock demonstrates notable resilience in a challenging market.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as the market reacts to escalating geopolitical tensions stemming from President Trump's aggressive rhetoric regarding Greenland and proposed tariffs on European allies. Community discussions reflect widespread anxiety over potential economic instability and a significant market sell-off, with many anticipating continued downside amid concerns about international relations and a carry trade unwind.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group is trending following its announcement of acquiring a wine authentication and trading business, coupled with a recent public offering and a positive profit outlook. This has fueled sharp price volatility, dividing the community between those calling it a "Chinese pump and dump" and others who view the dips as a buying opportunity in this low-float stock. The intense discussion reflects strong speculative interest and reactions to recent corporate developments.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending due to its planned split into two independent companies by 2026 and recent analyst downgrades, sparking an intense community debate. Many investors view the stock as deeply undervalued with an attractive dividend yield, believing current prices present a significant buying opportunity amidst accusations of market manipulation. The community largely anticipates value creation from the corporate separation, positioning KHC as a defensive play during broader market uncertainty.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid an intensifying bidding war, as Netflix recently revised its acquisition offer to all-cash for its studio and streaming assets. This move aims to counter Paramount Skydance's rival all-cash bid, though WBD's board continues to favor Netflix's proposal, citing concerns over Paramount's financing and the complexities of a potential breakup, leaving shareholders debating the superior path forward.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies Global is trending following a strategic private placement with Medtronic and the enrollment of the first patients in its pivotal PARADIGM trial for the DurAVR heart valve. This dual news has ignited intense community discussion, with many viewing Medtronic's involvement as a strong validation and anticipating significant appreciation. However, others express concern over potential dilution from the associated public offering despite the positive developments.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid news of new contracts with the U.S. Army for AI-driven logistics and the Department of Health and Human Services to establish a unified national health-data platform. This recent federal traction, combined with a deepened Microsoft partnership and high short interest, is driving intense debate between those anticipating a major turnaround and skeptics pointing to persistent revenue challenges and insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7%

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 8,454,052...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm...

Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) CEO Markus Warmuth sold 5,466 shares of the business's stock in a transaction on Wednesday, January 7th. The shares were sold at an...

<ul class="summary-bullets"><li>The company announced pricing of pre-funded warrants to purchase an additional 1.375 million shares at $23.9999 per warrant.</li><li>Monte Rosa also provided underwriters with a 30-day option to purchase up to 1.875 million additional shares at the public offering price.</li><li>The transaction is expected to close by January 12, 2026.</li></ul>Shares of Monte Rosa Therapeutics (GLUE) remain on the retail radar this week after the company priced a $300 million underwritten public offering at a discount to its last closing price.&nbsp;At the time of writing, <a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> fell 0.7% in premarket trading on Friday.&nbsp;The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31. Monte Rosa Therapeutics also announced pricing of pre-funded warrants to purchase an additional 1.375 million shares at $23.9999 per warrant.In addition, Monte Rosa also provided the underwriters with a 30-day option to purchase up to 1.875 million additional shares at the public offering price, net of underwriting discounts and commissions. All shares and pre-funded warrants in the offering are being sold by the company.The transaction is expected to close on or about January 12, 2026, with Jefferies, TD Cowen, and Piper Sandler serving as joint book-running managers for the offering. The $300 million raise represents an upsizing from the $200 million offering announced earlier this week.<h2 class="st-heading-2">Stock On Retail Radar</h2>The stock has been in the limelight lately. On Wednesday, GLUE shares surged more than 50% in premarket, before paring some of the gains after the opening bell. The move followed the <a href="https://stocktwits.com/news-articles/markets/equity/why-did-glue-stock-surge-over-50-in-premarket-today-1/cmxzbnHR42E">release</a> of encouraging interim Phase 1 data for MRT-8102 showing strong anti-inflammatory effects in patients with elevated cardiovascular risk.In the study, C-reactive protein levels fell by 85% after four weeks of treatment, with most participants reaching levels associated with lower cardiovascular risk. The drug also delivered deep and sustained target engagement across multiple dose levels. Based on the results, the company plans to advance MRT-8102 into a Phase 2 study later this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the premarket slide, retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes. GLUE was among the top trending tickers at the time of writing.<img src="https://news.stocktwits-cdn.com/GLUE_jpg_c79d022259.webp" alt="GLUE.jpg">One user said that the offer price came in higher than expected.<stembedurl>https://stocktwits.com/JacquelineWilder431/message/641308567</stembedurl>Over the past year, GLUE stock has surged nearly 300%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-aqst-stock-plunge-40-in-pre-market-today/cmU2g5ER4df">Why Did AQST Stock Plunge 40% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount

The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31.

Equity

<ul class="summary-bullets"><li>Investors brace for twin triggers in trade today: December jobs data and potential Supreme Court ruling on the legality of tariffs.&nbsp;</li><li>The jobs data is expected to dictate whether the Federal Reserve continues its aggressive pivot or hits the brakes on rate cuts.</li><li>Retail sentiment on Stocktwits showed caution toward SPY, while bullishness around tech-heavy QQQ intensified.</li></ul>U.S. stock futures were signaling a cautious start early Friday, with investors watching for two crucial triggers: December jobs data and a potential U.S. Supreme Court ruling on the legality of President Donald Trump’s tariff authority. This verdict could have wide implications for markets and trade policy. As of 3:30 a.m. ET on Friday, Nasdaq 100 futures, S&amp;P 500 futures, Dow futures and the Russell 2000 futures traded flat.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, moved to ‘neutral’ from ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has flipped back to ‘extremely bullish’ from ‘bullish’ a day ago, amid high message volumes.Trending Stocks To Watch Nvidia (NVDA): TSMC, its key manufacturing partner, reported a roughly 20% rise in revenue. Intel (INTC): Trump said he had a ‘great meeting’ with CEO Lip-Bu Tan yesterday.&nbsp;Chevron (CVX), Exxon Mobil (XOM), and SLB (SLB): Stocks are in focus after reports that senior executives from major oil companies are set to meet President Donald Trump, raising expectations around energy policy and domestic production.Disney (DIS): China’s Vice Premier Ding Xuexiang reportedly met Disney CEO Bob Iger in Beijing, encouraging further investment.&nbsp;Glencore (GNLCY): Reports suggest that Rio Tinto is in early talks with Glencore about a potential tie-up that could create the world’s largest mining company, with a combined valuation of nearly $207 billion.General Motors (GM): The company disclosed $7.1 billion in special charges tied to scaling back EV ambitions and restructuring its China operations.Tilray Brands (TLRY): Posted record fiscal Q2 revenue of $218 million, beating Street estimates.&nbsp;Johnson &amp; Johnson (JNJ):&nbsp;Has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-cuts-deal-with-trump-s-white-house-to-slash-drug-prices-and-dodge-tariffs/cmU2GbnR45p">secured</a> a tariff exemption in exchange for lower drug prices and two new U.S. manufacturing plants as part of its $55B domestic investment plan.&nbsp;CorMedix Therapeutics (CRMD): The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cor-medix-stock-rises-after-hours-ceo-locks-in-chairman-seat-bigger-paycheck-and-rich-severance/cmU2TRJR45s">disclosed</a> an expanded role and revised employment terms for CEO Joseph Todisco, following a sharp selloff earlier in the session tied to cautious guidance.Oscar Health: Shares rose nearly 7% after hours after gaining about 3% in regular trading, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">investors reacted to a House vote backing</a> ACA subsidy extensions, despite a disclosed insider share sale.Opendoor Technologies (OPEN), Rocket Companies (RKT), Offerpad Solutions (OPAD), UWM Holdings (UWMC): U.S. President Donald Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rkt-stock-rallies-on-trump-pledge-to-keep-mortgage-rates/cmU2R4KR45A">said</a> Thursday that he is working to lower mortgage rates for Americans, following several years of elevated borrowing costs.Monte Rosa Therapeutics (GLUE): Shares are in focus after the biotech priced a $300M public offering at $24 per share.&nbsp;Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;Ondas Holdings&nbsp;(<a href="https://stocktwits.com/news-articles/markets/equity/onds-stock-soars-to-5-year-highs-on-israel-defense-tie-ups-rebrand-buzz/cmUcUPnR45V">ONDS</a>),&nbsp;Oscar Health Inc. (<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">OSCR</a>), Security Matters (SMX), Baidu (BIDU), Him &amp; Hers Health (HIMS), among others.&nbsp;&nbsp; Other Catalysts To Watch On the economic front, investors are looking ahead to the release of the December Jobs Report at 8:30 a.m. ET. Economists expect the unemployment rate to tick down to 4.5%. Traders will also be listening closely to FOMC Member Neel Kashkari, who is scheduled to speak at 10:00 a.m. ET.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD Are On Traders' Radar Today

Early signals show futures flat, SPY sentiment cooling, and tech traders turning bullish.

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.

Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Wells Fargo & Company lifted their price target on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday...

Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $34.00 Price Target at Guggenheim

Guggenheim increased their target price on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a "buy" rating in a research note on Thursday...

Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable 

Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why

Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

GLUE
Monte Rosa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GLUE News

GLUEMonte Rosa Therapeutics Inc